A randomised cross-over study of effects of vasodilator treatment on left ventricular mass and volume in patients with chronic aortic regurgitatio
Phase 3
Not yet recruiting
- Conditions
- aortic regurgitationCardiovascular - Other cardiovascular diseases
- Registration Number
- ACTRN12610000753055
- Lead Sponsor
- ational Heart Foundation of NZ
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Moderate or severe asymptomatic aortic regurgitation
Exclusion Criteria
current indication for aortic valve replacement
other clinically significant cardiac disease
contraindication to cardiac magnetic resonance imaging
atrial fibrillation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie vasodilator effects on left ventricular mass in chronic aortic regurgitation?
How does vasodilator treatment compare to standard-of-care in managing chronic aortic regurgitation patients?
Are there specific biomarkers that predict response to vasodilator therapy in chronic aortic regurgitation?
What adverse events are associated with vasodilator use in chronic aortic regurgitation and how are they managed?
What combination therapies or alternative drugs show promise for chronic aortic regurgitation alongside vasodilators?